Noninvasive 11C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis

Elizabeth Tucker, Beatriz Guglieri-Lopez, Alvaro Ordonez Suarez, Brittaney Ritchie, Mariah H. Klunk, Richa Sharma, Yong S. Chang, Julian Sanchez-Bautista, Sarah Frey, Martin Lodge, Steven Rowe, Daniel Holt, Jogarao V.S. Gobburu, Charles A. Peloquin, William B Mathews, Robert F Dannals, Carlos A Pardo-Villamizar, Sujatha Kannan, Vijay D. Ivaturi, Sanjay Jain

Research output: Contribution to journalArticle

Abstract

Tuberculous meningitis (TBM) is a devastating form of tuberculosis (TB), and key TB antimicrobials, including rifampin, have restricted brain penetration. A lack of reliable data on intralesional drug biodistribution in infected tissues has limited pharmacokinetic (PK) modeling efforts to optimize TBM treatments. Current methods to measure intralesional drug distribution rely on tissue resection, which is difficult in humans and generally limited to a single time point even in animals. In this study, we developed a multidrug treatment model in rabbits with experimentally induced TBM and performed serial noninvasive dynamic 11C-rifampin positron emission tomography (PET) over 6 weeks. Area under the curve brain/plasma ratios were calculated using PET and correlated with postmortem mass spectrometry. We demonstrate that rifampin penetration into infected brain lesions is limited, spatially heterogeneous, and decreases rapidly as early as 2 weeks into treatment. Moreover, rifampin concentrations in the cerebrospinal fluid did not correlate well with those in the brain lesions. First-in-human 11C-rifampin PET performed in a patient with TBM confirmed these findings. PK modeling predicted that rifampin doses (≥30 mg/kg) were required to achieve adequate intralesional concentrations in young children with TBM. These data demonstrate the proof of concept of PET as a clinically translatable tool to noninvasively measure intralesional antimicrobial distribution in infected tissues.

Original languageEnglish (US)
Article numberaau0965
JournalScience Translational Medicine
Volume10
Issue number470
DOIs
StatePublished - Dec 5 2018

Fingerprint

Meningeal Tuberculosis
Rifampin
Positron-Emission Tomography
Pharmaceutical Preparations
Brain
Tuberculosis
Pharmacokinetics
Area Under Curve
Cerebrospinal Fluid
Mass Spectrometry
Therapeutics
Rabbits

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Noninvasive 11C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis. / Tucker, Elizabeth; Guglieri-Lopez, Beatriz; Ordonez Suarez, Alvaro; Ritchie, Brittaney; Klunk, Mariah H.; Sharma, Richa; Chang, Yong S.; Sanchez-Bautista, Julian; Frey, Sarah; Lodge, Martin; Rowe, Steven; Holt, Daniel; Gobburu, Jogarao V.S.; Peloquin, Charles A.; Mathews, William B; Dannals, Robert F; Pardo-Villamizar, Carlos A; Kannan, Sujatha; Ivaturi, Vijay D.; Jain, Sanjay.

In: Science Translational Medicine, Vol. 10, No. 470, aau0965, 05.12.2018.

Research output: Contribution to journalArticle

Tucker, Elizabeth ; Guglieri-Lopez, Beatriz ; Ordonez Suarez, Alvaro ; Ritchie, Brittaney ; Klunk, Mariah H. ; Sharma, Richa ; Chang, Yong S. ; Sanchez-Bautista, Julian ; Frey, Sarah ; Lodge, Martin ; Rowe, Steven ; Holt, Daniel ; Gobburu, Jogarao V.S. ; Peloquin, Charles A. ; Mathews, William B ; Dannals, Robert F ; Pardo-Villamizar, Carlos A ; Kannan, Sujatha ; Ivaturi, Vijay D. ; Jain, Sanjay. / Noninvasive 11C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis. In: Science Translational Medicine. 2018 ; Vol. 10, No. 470.
@article{65369136503e4a9e8dbfc08d1fcb4418,
title = "Noninvasive 11C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis",
abstract = "Tuberculous meningitis (TBM) is a devastating form of tuberculosis (TB), and key TB antimicrobials, including rifampin, have restricted brain penetration. A lack of reliable data on intralesional drug biodistribution in infected tissues has limited pharmacokinetic (PK) modeling efforts to optimize TBM treatments. Current methods to measure intralesional drug distribution rely on tissue resection, which is difficult in humans and generally limited to a single time point even in animals. In this study, we developed a multidrug treatment model in rabbits with experimentally induced TBM and performed serial noninvasive dynamic 11C-rifampin positron emission tomography (PET) over 6 weeks. Area under the curve brain/plasma ratios were calculated using PET and correlated with postmortem mass spectrometry. We demonstrate that rifampin penetration into infected brain lesions is limited, spatially heterogeneous, and decreases rapidly as early as 2 weeks into treatment. Moreover, rifampin concentrations in the cerebrospinal fluid did not correlate well with those in the brain lesions. First-in-human 11C-rifampin PET performed in a patient with TBM confirmed these findings. PK modeling predicted that rifampin doses (≥30 mg/kg) were required to achieve adequate intralesional concentrations in young children with TBM. These data demonstrate the proof of concept of PET as a clinically translatable tool to noninvasively measure intralesional antimicrobial distribution in infected tissues.",
author = "Elizabeth Tucker and Beatriz Guglieri-Lopez and {Ordonez Suarez}, Alvaro and Brittaney Ritchie and Klunk, {Mariah H.} and Richa Sharma and Chang, {Yong S.} and Julian Sanchez-Bautista and Sarah Frey and Martin Lodge and Steven Rowe and Daniel Holt and Gobburu, {Jogarao V.S.} and Peloquin, {Charles A.} and Mathews, {William B} and Dannals, {Robert F} and Pardo-Villamizar, {Carlos A} and Sujatha Kannan and Ivaturi, {Vijay D.} and Sanjay Jain",
year = "2018",
month = "12",
day = "5",
doi = "10.1126/scitranslmed.aau0965",
language = "English (US)",
volume = "10",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "470",

}

TY - JOUR

T1 - Noninvasive 11C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis

AU - Tucker, Elizabeth

AU - Guglieri-Lopez, Beatriz

AU - Ordonez Suarez, Alvaro

AU - Ritchie, Brittaney

AU - Klunk, Mariah H.

AU - Sharma, Richa

AU - Chang, Yong S.

AU - Sanchez-Bautista, Julian

AU - Frey, Sarah

AU - Lodge, Martin

AU - Rowe, Steven

AU - Holt, Daniel

AU - Gobburu, Jogarao V.S.

AU - Peloquin, Charles A.

AU - Mathews, William B

AU - Dannals, Robert F

AU - Pardo-Villamizar, Carlos A

AU - Kannan, Sujatha

AU - Ivaturi, Vijay D.

AU - Jain, Sanjay

PY - 2018/12/5

Y1 - 2018/12/5

N2 - Tuberculous meningitis (TBM) is a devastating form of tuberculosis (TB), and key TB antimicrobials, including rifampin, have restricted brain penetration. A lack of reliable data on intralesional drug biodistribution in infected tissues has limited pharmacokinetic (PK) modeling efforts to optimize TBM treatments. Current methods to measure intralesional drug distribution rely on tissue resection, which is difficult in humans and generally limited to a single time point even in animals. In this study, we developed a multidrug treatment model in rabbits with experimentally induced TBM and performed serial noninvasive dynamic 11C-rifampin positron emission tomography (PET) over 6 weeks. Area under the curve brain/plasma ratios were calculated using PET and correlated with postmortem mass spectrometry. We demonstrate that rifampin penetration into infected brain lesions is limited, spatially heterogeneous, and decreases rapidly as early as 2 weeks into treatment. Moreover, rifampin concentrations in the cerebrospinal fluid did not correlate well with those in the brain lesions. First-in-human 11C-rifampin PET performed in a patient with TBM confirmed these findings. PK modeling predicted that rifampin doses (≥30 mg/kg) were required to achieve adequate intralesional concentrations in young children with TBM. These data demonstrate the proof of concept of PET as a clinically translatable tool to noninvasively measure intralesional antimicrobial distribution in infected tissues.

AB - Tuberculous meningitis (TBM) is a devastating form of tuberculosis (TB), and key TB antimicrobials, including rifampin, have restricted brain penetration. A lack of reliable data on intralesional drug biodistribution in infected tissues has limited pharmacokinetic (PK) modeling efforts to optimize TBM treatments. Current methods to measure intralesional drug distribution rely on tissue resection, which is difficult in humans and generally limited to a single time point even in animals. In this study, we developed a multidrug treatment model in rabbits with experimentally induced TBM and performed serial noninvasive dynamic 11C-rifampin positron emission tomography (PET) over 6 weeks. Area under the curve brain/plasma ratios were calculated using PET and correlated with postmortem mass spectrometry. We demonstrate that rifampin penetration into infected brain lesions is limited, spatially heterogeneous, and decreases rapidly as early as 2 weeks into treatment. Moreover, rifampin concentrations in the cerebrospinal fluid did not correlate well with those in the brain lesions. First-in-human 11C-rifampin PET performed in a patient with TBM confirmed these findings. PK modeling predicted that rifampin doses (≥30 mg/kg) were required to achieve adequate intralesional concentrations in young children with TBM. These data demonstrate the proof of concept of PET as a clinically translatable tool to noninvasively measure intralesional antimicrobial distribution in infected tissues.

UR - http://www.scopus.com/inward/record.url?scp=85058108235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058108235&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aau0965

DO - 10.1126/scitranslmed.aau0965

M3 - Article

C2 - 30518610

AN - SCOPUS:85058108235

VL - 10

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 470

M1 - aau0965

ER -